- Home
- FLX vs ORIC Comparison
FLX vs ORIC Comparison
Compare FLX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- ORIC
- Stock Information
- Founded
- FLX 2013
- ORIC 2014
- Country
- FLX China
- ORIC United States
- Employees
- FLX N/A
- ORIC N/A
- Industry
- FLX
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- FLX
- ORIC Health Care
- Exchange
- FLX NYSE
- ORIC Nasdaq
- Market Cap
- FLX 603.7M
- ORIC 633.7M
- IPO Year
- FLX 2024
- ORIC 2020
- Fundamental
- Price
- FLX $8.02
- ORIC $10.12
- Analyst Decision
- FLX
- ORIC Strong Buy
- Analyst Count
- FLX 0
- ORIC 9
- Target Price
- FLX N/A
- ORIC $18.75
- AVG Volume (30 Days)
- FLX 15.6K
- ORIC 572.3K
- Earning Date
- FLX 02-27-2025
- ORIC 03-10-2025
- Dividend Yield
- FLX N/A
- ORIC N/A
- EPS Growth
- FLX N/A
- ORIC N/A
- EPS
- FLX 0.19
- ORIC N/A
- Revenue
- FLX $663,142,775.00
- ORIC N/A
- Revenue This Year
- FLX N/A
- ORIC N/A
- Revenue Next Year
- FLX N/A
- ORIC N/A
- P/E Ratio
- FLX $44.21
- ORIC N/A
- Revenue Growth
- FLX 1.31
- ORIC N/A
- 52 Week Low
- FLX $6.50
- ORIC $6.33
- 52 Week High
- FLX $21.95
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- ORIC 56.26
- Support Level
- FLX N/A
- ORIC $9.39
- Resistance Level
- FLX N/A
- ORIC $11.15
- Average True Range (ATR)
- FLX 0.00
- ORIC 0.74
- MACD
- FLX 0.00
- ORIC 0.16
- Stochastic Oscillator
- FLX 0.00
- ORIC 60.49
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.